Last reviewed · How we verify
NCT06055660
Moesin Expression in Clear Cell Renal Cell Carcinoma
trial testing Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma in Renal Cell Carcinoma in 50 participants. Completed in 31 December 2021.
31 October 2021
Quick facts
| Lead sponsor | Sohag University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 1 January 2017 |
| Primary completion | 31 October 2021 |
| Estimated completion | 31 December 2021 |
Drugs / interventions tested
- Immunohistochemical detection of Moesin in Clear cell Renal Cell Carcinoma
Conditions studied
- Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →
Sponsor
Sohag University
Who can join
Eligibility, any sex, with Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Renal cell carcinoma (RCC) is the most frequently occurring primary renal neoplasm. There are several histological variants of RCC that are associated with variable prognostic outcomes. Epithelial-mesenchymal transition (EMT) is a phenomenon in which the epithelial cells acquire some mesenchymal criteria as enhanced invasive potential. There are several cell surface molecules that are implicated in EMT. Moesin is one of these molecules that is involved in EMT, which is associated with enhanced invasive potential and poor prognosis. Targeting Moesin by novel therapeutic agents may prevent EMT and improve prognosis of patients with RCC.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Epithelial-Mesenchymal Transition in Cancer: Insights Into Therapeutic Targets and Clinical Implications.
Srinivasan D, Balakrishnan R, Chauhan A, Kumar J, et al · · 2025 · cited 5× · PMID 40895189 · DOI 10.1002/mco2.70333
Verify or expand the search:
- PubMed search for NCT06055660
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Cell Carcinoma
Currently open trials in the same condition.
- NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
- NCT07195682 — A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting
- NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
Other Sohag University trials
Trials by the same sponsor.
- NCT07119905 — Association Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patie · not yet recruiting
- NCT07512219 — Comparison Between Greater Occipital Nerve Block and Pulsed Radiofrequency in the Management of Chronic Migraine · NA · not yet recruiting
- NCT07519694 — Comparative Study Between Different Additives to Lidocaine 2٪ for Peribulbar Block in Vitreoretinal Surgery · NA · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
- NCT07523386 — Compartive Study Between Cannulated Screw and Kws in Fixation of Distal Radius · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06055660 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sohag University
- Last refreshed: 28 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06055660.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing